细胞膜糖蛋白P170 抑制剂的研究进展

摘要/Abstract

摘要： 多药耐药性的发生是肿瘤治疗失败的原因之一, 而肿瘤细胞多药耐药基因1(MDR1) 编码的细胞膜糖蛋白P170 表达的增加是最常见的发生机制。近年来针对细胞膜糖蛋白P170 抑制剂的研究有了很大进展, 本文就目前细胞膜糖蛋白P170 抑制剂的研究状况进行综述。

关键词: 肿瘤, 多药耐药, P-糖蛋白, 基因表型

Abstract: Multidrug resistance (MDR) is one of the major obstacles to cancer chemotherapy. It is now well established that MDR phenotype is strongly correlated with the over-expression of P-glycoprotein (P-gp), a membrane glycoprotein encoded by MDR1 gene. There is very great progress in the research of the P-gp inhibitors in recent years. This article describes the current research state of the P-gp inhibitors.

Key words: tumor, multidrug resistance, P-glycoprotein inhibitor, phenotype

中图分类号:

R963

张育. 细胞膜糖蛋白P170 抑制剂的研究进展[J]. 中国临床药理学与治疗学, 2004, 9(10): 1087-1090.

ZHANG Yu. Progress in the research of P-gp inhibitors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1087-1090.

参考文献

1 Gottesman MM, Fojo T, Bates SE.Multidrug resistance in cancer: role of ATP-dependent transporters[J]. Nat Rev Cancer, 2002; 2(1): 48-58
2 Dean M, Rzhetsky A, Allikmets R.The human ATP-binding cassette (ABC ) transporter superfamily [J]. Genome Res, 2001;11(7): 1156-66
3 Shoshani T, Zhang S, Dey S, Pastan I, GottesmanMM.Analysis of random recombination between human MDR1 and Mouse MDR1a cDNA in a pHMDR-Dihydrofolate reductase bicistronic expression system[J]. Mol Pharmacol, 1998; 54(4): 623-30
4 Loo TW, Bartlett MC, Clarke DM. Drug binding in human Pglycoprotein causes conformational changes in both nucleotidebinding domains[J]. J Biol Chem 2003;278(50): 1575-8
5 Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter[J]. Annu Rev Biochem, 1993; 62(10): 385-427
6 Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918[J]. Clin Cancer Res, 1996; 2(1): 7-12
7 Ernest S, Bello-Reuss E.Expression and function of P-gly coprotein in a mouse kiney cell line[J]. Am J Physiol, 1995; 269 (2 Pt 1): C323-33
8 Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A.Active secretion of drug form the intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier[J]. J Pharm Pharmacol, 1996;48(10): 1083-9
9 Roman RM, Wang Y, Lidofsky SD, Feranchak AP, Lomri N, Scharschmidt BF, et al. Hepatocellular ATP-binding cassette protein expression enhances ATP release and autocrine regulation of cell volume[J]. J Biol Chem, 1997;272(35): 1970-6
10 Wu J, Zhang JJ, Koppel H, Jacob TJ.P-gly coprotein regulates a volume-actived chloride current in bovine non-pigmented ciliary epithelial cells[J]. J Physcol, 1996;491(Pt3): 743-55
11 Borst P, Zelcer N, van Helvoort A.ABC transporters in lipid transport[J]. Biochem Biophys Acta, 2000;1486(1): 128-44
12 Bello-Reuss E, Ernest S, Holland OB, Hellmich MR.Role of multidrug resistance P-gly coprotein in the secretion of aldosterone by human adrenal NCI-H295 cells[J]. Am J Phy siol Cell Physiol, 2000;278(6): C1256-65
13 Fardel O, Lecureur V, Guillouzo A.The P-glycoprotein multidrug transporter[J]. Gen Pharmcol, 1996;27(8): 1283-91
14 Ambudkar SV, Dey S, Hry cyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter[J]. Annu Rev Pharmacol Toxicol, 1999;39(4): 361-98
15 Krishna R, Mayer LD.Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer srug[J]. Eur J Pharm Sci, 2000;11(4): 265-83
16 Te Boekhorst PA, Van KJ, Schoester M, Sonneveld P.Reversal of typical multidrug resistance by cyclosporin and its non-immunosupressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype[J]. Cancer Chemother Pharmcol, 1992;30(3): 238-42
17 Coley HM, Verrill MW, Gregson SE.Inciduce of P-glycoprotien over expression and mutidrug resistance(MDR) reversal in adult soft tissue sarcoma[J]. Eur J Cancer, 2000;36(7): 881-8
18 Minami H, Ohtsu T, Fujii H, Igarashi T, Itoh K, Uchiyama-Kokubu N, et al. Phase Ⅰ study of Intravenous PSC-833 and doxorubicin: Reversal of multidrug resistance[J]. Jpn J Cancer Res, 2001; 92(2): 220-30
19 Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, LitchmanM, A phase Ⅰ trial of doxorubicin, and paclitaxel, and valspodar(PSC833), a modulator of multidrug resistance[J]. Clin Cancer Res, 2001; 7(5): 1221-9
20 Baekelandt M, Lehne G, Trope CG, Szanto I, Pfeiffer P, Gustavssson B, et al. Phase Ⅰ Ⅱ trial of the multidrug-resistance modulator valspodar combined ith cisplatin and doxorubicin in refractory ocarian cancer[J]. J Clin Oncol, 2001;19 (12): 2983-93
21 Baekelandt M, Lehne G, Trope CG, Szanto I, Pfeiffer P, Gustavssson B, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-gly coprotein-mediated multidrug resistance in vitro [J]. Anticancer Drugs, 1997; 8(2): 125-40
22 Pritchard-Jones K.BIRICODIA(VX-710; Incel): an effective chemosensitizer in neuroblastoma[J]. Br J Cancer, 1999;80 (8): 1190-6
23 Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, et al. A phase Ⅱ study of MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy[J]. Gynecol Oncol, 2002;86(3): 302-10
24 Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD, et al. Safety and efficacy of the MDR inhibitor Incel(biricodar, VX-710 ) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer[J]. Cancer Chemother Pharmacol, 2003;51(4): 297-305
25 Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, et al. Safety and efficacy of the multidrug resistance inhibitor Incel(biricodar; VX-710) in combination with mitoxantrone for advanced breast cancer refractory to paclitaxel[J]. Clin Cancer Res, 2002;8(3): 670-8
26 Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies[J]. Cancer Res, 1999;59 (16): 3944-8
27 Lum BL, Gosland MP.MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitor[J]. Hematol Oncol Clin North Am, 1995; 9(24 Pt 1): 319-36
28 Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, et al. In vitro and in vivo reversal of P-glycoproteinmediated multidrug resistance by a novel potent modulator, XR9576[J]. Cancer Res, 2001;61(2): 749-58
29 Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P.A phase Ⅰ study trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56 +lymphocytes after oral and intravenous administration[J]. Clin Cancer Res, 2000;6(11): 4186-91
30 Thomas H, Coley HM. Overcoming multidrug resistance in Cancer: An update on the clinical strategy of inhibiting P-glycoprotein[J]. Cancer control, 2003;10(2): 159-65
31 Goldman B. Multidrug resistance: Can new drugs help chemotherapy score against cancer[J]. JNCI, 2003; 95(4): 255-7
32 NewmanMJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-medited multidrug resistance[J]. Cancer Res, 2000; 60(11): 2964-72

[1]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[2]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[3]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[4]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[5]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[6]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[7]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[8]	刘丹, 刘明, 金良友, 潘娟, 辛昊儒, 刘梦圆, 李鑫, 郑坤, 冯晓灵. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1168-1176.
[9]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[10]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[11]	高丽丽, 王玉珠, 王燕, 李健, 王骏. 抗肿瘤抗体偶联药物临床药理学研究的若干问题与考虑[J]. 中国临床药理学与治疗学, 2023, 28(1): 75-85.
[12]	刘佳佳, 高岩, 张业慧, 武静. CRABP2在肿瘤发生发展中的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 86-92.
[13]	洪子强, 苟文曦, 崔百强, 白向豆, 金大成, 苟云久. m7G甲基转移酶METTL1在肿瘤中的作用[J]. 中国临床药理学与治疗学, 2023, 28(1): 93-100.
[14]	缪亚东, 李蹊, 王燕, 高坡, 周敏, 于浩. 抗肿瘤药物临床试验数据管理的一般考虑[J]. 中国临床药理学与治疗学, 2022, 27(9): 1055-1060.
[15]	王亚丽, 霍续磊, 陈峰, 李生兰, 郑晓红, 王灿, 李文斌. 硝呋莫司抗肿瘤作用的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 955-960.